Link: https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-evusheld-not-currently-authorized-emergency-use-us
Description: WebJan 26, 2023 · Based on this revision, Evusheld is not currently authorized for use in the U.S. until further notice by the Agency. Data show Evusheld is unlikely to be active against certain SARS-CoV-2...
DA: 9 PA: 91 MOZ Rank: 6
Link: https://www.fda.gov/media/154702/download
Description: WebEVUSHELD is an investigational medicine used in adults and adolescents (12 years of age and older who weigh at least 88 pounds [40 kg]) for pre-exposure prophylaxis for prevention of COVID-19 in...
DA: 85 PA: 70 MOZ Rank: 9
Link: https://www.evusheld.com/en/patient/resources
Description: WebAUTHORIZED USE. EVUSHELD is an unapproved medicine used in adults and adolescents (12 years of age and older who weigh at least 88 pounds [40 kg]) for pre-exposure prophylaxis for prevention of COVID-19 in persons who are: Not currently infected with SARS-CoV-2 and who have not had recent known close contact with someone who …
DA: 59 PA: 75 MOZ Rank: 31
Link: https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld
Description: WebOverview. Evusheld is a medicine used to prevent COVID-19 in adults and adolescents (from 12 years of age weighing at least 40 kilograms). It is also used to treat COVID-19 in adults and adolescents who do not require supplemental oxygen and who are at increased risk of the disease becoming severe. Evusheld contains two active substances ...
DA: 94 PA: 33 MOZ Rank: 74
Link: https://en.wikipedia.org/wiki/Tixagevimab/cilgavimab
Description: WebTixagevimab/cilgavimab, sold under the brand name Evusheld, is a combination of two human monoclonal antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061) targeted against the surface spike protein of SARS …
DA: 84 PA: 39 MOZ Rank: 47
Link: https://www.fda.gov/media/154701/download
Description: WebEVUSHELD has been authorized by FDA for the emergency use described above. EVUSHELD is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19.
DA: 14 PA: 75 MOZ Rank: 84
Link: https://aspr.hhs.gov/COVID-19/Therapeutics/Products/Evusheld/Pages/default.aspx
Description: WebImportant Evusheld Updates. April 7, 2023: Find Evusheld Shelf-Life Expiration Dates in the Searchable COVID-19 Therapeutic Product Database. January 26, 2023: FDA Announces Evusheld is Not Currently Authorized for Use in the U.S.
DA: 8 PA: 95 MOZ Rank: 2
Link: https://www.astrazeneca.com/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html
Description: WebDec 8, 2021 · AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorisation (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.
DA: 30 PA: 6 MOZ Rank: 66
Link: https://www.astrazeneca-us.com/media/press-releases/2021/evusheld-formerly-AZD7442-long-acting-antibody-combination-authorized-for-emergency-use-in-the-US-for-pre-exposure-prophylaxis-prevention-of-COVID-191.html
Description: WebDec 8, 2021 · EVUSHELD is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorized in the US for COVID-19 pre-exposure prophylaxis and the only COVID-19 antibody delivered as an intramuscular dose (150mg tixagevimab and 150mg cilgavimab).
DA: 23 PA: 26 MOZ Rank: 67
Link: https://www.astrazeneca-us.com/media/press-releases/2023/update-on-us-food-and-drug-administration-emergency-use-authorization-of-evusheld.html
Description: WebJan 26, 2023 · EVUSHELD is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to EVUSHELD. WARNINGS AND PRECAUTIONS. Hypersensitivity Including Anaphylaxis. Serious hypersensitivity reactions, including anaphylaxis, have been observed with EVUSHELD.
DA: 2 PA: 11 MOZ Rank: 5
